Phase II failure sees stock plunge and job cutbacks for Infinity Pharmaceuticals
June 15, 2016Research and Development, Sales and Marketing AbbVie, infinity pharmaceuticals, non-Hodgkin lymphoma, trial failure
Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin …
Sobi says US FDA approves higher dose of Orfadin to treat rare genetic disorder
June 15, 2016Research and Development, Sales and Marketing US FDA, genetic disorder, regulation, sobi
Swedish Orphan Biovitrum AB (Sobi) on Wednesday said the US Food and Drug Administration (FDA) has approved a higher strength …
FDA issues warnings on Janssen, AstraZeneca diabetes drugs
June 15, 2016Research and Development, Sales and Marketing AstraZeneca, FDA, Janssen, farxiga, invokana
The US Food and Drug Administration has issued a warning of the risk of acute kidney injury for the type-2 …
German Supreme Court grants Lilly appeal to block Alimta generics
June 15, 2016Research and Development, Sales and Marketing Actavis, Alimta, Eli Lilly
Eli Lilly (NYSE: LLY) has announced that it has been granted an appeal by the German Federal Supreme Court, in …
Actelion says blood pressure drug Uptravi now available in Germany
June 15, 2016Research and Development, Sales and Marketing Actelion, EU, blood pressure, product launch
Actelion (SIX: ATLN) said its high blood pressure drug Uptravi (selexipag) is now available in Germany. The European Commission granted …
Novartis says to develop antimalarial treatment with Medicines for Malaria Venture
June 15, 2016Research and Development, Sales and Marketing Novartis, antimalarial drug, drug trial
Swiss pharma major Novartis (NYSE: NVS) said it has partnered with Medicines for Malaria Venture (MMV) and the Bill & Melinda …
Shire adds to gastrointestinal portfolio with Pfizer compound acquisition
June 14, 2016Research and Development, Sales and Marketing Pfizer, Shire, acquisition, compound
Shire (LSE: SHP) has announced that it has acquired an investigational biologic for the treatment inflammatory bowel disease from Pfizer …
Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study
June 14, 2016Manufacturing and Production, Research and Development Janssen, blood cancer, drug trial, imbruvica
Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival …
Marinus says will stop developing adult focal onset seizure drug as Phase III trials fail; shares plunge
June 14, 2016Manufacturing and Production, Research and Development Drug-Resistant Epilepsy, Marinus Pharmaceuticals, drug trial, ganaxolone
Shares in Marinus Pharmaceuticals (Nasdaq: MRNS) more than halved in value Monday after the company said it plans to stop …
MSD insulin glargine biosimilar meets primary endpoint in late-stage trials
June 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Merck, biosimilar, insulin, insuline glargine
MSD (NYSE: MRK), known as Merck in the US and Canada, has announced results from two Phase III studies evaluating …
FDA to review data on Amgen’s Humira biosimilar
June 14, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, FDA, Humira, biosimilar
Amgen (NASDAQ: AMGN) has announced the US Food and Drug Administration’s (FDA) Arthritis Advisory Committee will review data supporting the …
Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients
June 14, 2016Manufacturing and Production, Research and Development Novo Nordisk, Victoza, drug trial, type 2 diabetes
Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of …
New COO appointed at X4 Pharmaceuticals
June 13, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
X4 Pharmaceuticals has announced the appointment of John K. Celebi as its new chief operating officer. Celebi will bring over …
Shire gets FDA breakthrough therapy designation for two rare disease drugs
June 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Shire, US FDA, rare disease, rare disease drugs
Ireland headquartered Shire (LSE: SHP) on Monday said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation …
Lilly showcases positive late-stage data in diabetes treatments
June 13, 2016Research and Development, Sales and Marketing diabetes, lilly
Eli Lilly (NYSE: LLY) has presented data on their diabetes drugs in late-stage trials at the 76th American Diabetes Association …
Weekly Movers: Lion Biotech, Adamis, Sarepta…
June 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Alexion, Biogen, Shares, Stock Markets, Stock Movement, drug trial, sarepta
Drug trial results remained the important theme over the past week with several companies announcing key study results. The trial …
Novo Nordisk presents Tresiba data showing significantly lower hypoglycaemia rates
June 13, 2016Research and Development, Sales and Marketing Novo Nordisk, Tresiba
Novo Nordisk (CPH: NOVO-B) has presented new Phase IIIb data on Tresiba (insulin degludec) at the American Diabetes Association annual …
Google’s DeepMind to apply artificial intelligence technology to NHS in next five years
June 13, 2016Medical Communications, Research and Development, Sales and Marketing DeepMind, NHS, collaboration, google, health tech
Google’s artificial intelligence company DeepMind Technologies wants to apply its machine learning technology to NHS patient data within the next …
Pfizer’s leukaemia drug beats chemotherapy in Phase III trials
June 13, 2016Research and Development, Sales and Marketing Inotuzumab ozogamicin, Pfizer, acute lymphoblastic leukaemia
Pfizer (NYSE: PFE) has announced data from a pivotal Phase III trial for acute lymphoblastic leukaemia (ALL) drug, inotuzumab ozogamicin, …
Shares in Global Blood jump after positive results for trial sickle cell drug
June 13, 2016Research and Development, Sales and Marketing Global Blood Therapeutics, drug trial, sickle cell disease
Global Blood Therapeutics (Nasdaq: GBT) shares jumped to close up over 9% Friday after the company said its trial drug …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
